BMEA

BMEA

USD

Biomea Fusion Inc. Common Stock

$2.610+0.140 (5.668%)

リアルタイム価格

Healthcare
バイオテクノロジー
米国

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$2.470

高値

$2.650

安値

$2.435

出来高

2.30M

企業ファンダメンタルズ

時価総額

98.1M

業種

バイオテクノロジー

United States

取引統計

平均出来高

1.91M

取引所

NMS

通貨

USD

52週レンジ

安値 $1.291現在値 $2.610高値 $13.07

関連ニュース

GlobeNewswire

Innovations in Imaging, such as AI-Enhanced Retinal & Fundus Camera Systems are Booming Along with Revenue Opportunities

PALM BEACH, Fla., June 04, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The Retinal and Fundis Camera market has shown growth in the recent years and is expected to continue for years to come. Fundus

もっと見る
Innovations in Imaging, such as AI-Enhanced Retinal & Fundus Camera Systems are Booming Along with Revenue Opportunities
Analyst Upgrades

Piper Sandler Assumes Biomea Fusion at Overweight, Announces Price Target of $7

Piper Sandler analyst Edward Tenthoff assumes Biomea Fusion with a Overweight rating and announces Price Target of $7.

もっと見る
Piper Sandler Assumes Biomea Fusion at Overweight, Announces Price Target of $7
Analyst Upgrades

D. Boral Capital Maintains Buy on Biomea Fusion, Maintains $16 Price Target

D. Boral Capital analyst Jason Kolbert maintains Biomea Fusion with a Buy and maintains $16 price target.

もっと見る
D. Boral Capital Maintains Buy on Biomea Fusion, Maintains $16 Price Target
GlobeNewswire

Biomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia

REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, today announced that preliminary clinical data from the

もっと見る
Biomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia